Brent Warner

Brent Warner is a distinguished professional with extensive experience in the pharmaceutical industry, particularly in the areas of gene therapy, rare diseases, marketing, and strategic operations.

Having held key positions at reputable companies such as Novartis, BioMarin Pharmaceutical Inc., Biogen, Baxalta, PODS, and Hamilton Communications, Brent Warner has showcased his expertise and leadership abilities throughout his career journey.

With his tenure at Novartis, Brent Warner excelled as the Vice President of the Gene Therapy and Rare Disease Franchise, demonstrating his strategic vision and business acumen in this specialized field.

Prior to his role at Novartis, Brent Warner held various pivotal roles at Biogen, including overseeing marketing initiatives for SPINRAZA and Rare Disease on a global scale, further solidifying his proficiency in marketing and launch strategies.

At BioMarin Pharmaceutical Inc., Brent Warner served as the North America Launch Leader for Gene Therapy - Hemophilia, showcasing his ability to drive successful product launches in a competitive market.

Additionally, Brent Warner's experience at Baxalta, PODS, and Hamilton Communications has equipped him with a comprehensive understanding of marketing, launch excellence, and strategic operations within the healthcare and pharmaceutical sectors.

His diverse background, encompassing roles in marketing, strategic operations, launch leadership, and executive positions, reflects Brent Warner's versatility and adaptability in navigating the intricacies of the pharmaceutical industry.

Overall, Brent Warner's career trajectory underscores his successful track record and his proficiency in driving business growth and innovation within the pharmaceutical landscape.